Figure 1From: Short versus standard treatment with pegylated interferon alfa-2A plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the cleo trial CLEO study design. During the treatment phase, all patients received PEG-IFN-α-2a 180 μg/week + ribavirin 800-1200 mg/day. PEG-IFN = pegylated interferonBack to article page